MDA-MB 231, a triple-negative breast cancer (TNBC), is an aggressive type of breast cancer and associated with early metastasis, drug resistance, and poor patient survival, which do not express estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Here, ESR1 is linked to breast carcinoma.